PDX model details
| PDX ID | 452C | 
|---|---|
| Host Strain(and Source) | NSG Source: Monash University | 
| Host Strain Immune system Humanized | NO | 
| Host Type | Testosterone supplemented | 
| Graft Site | Subcutaneous | 
| Current Generation (* indicates number of generations grown in Castrate host) | 6 | 
| Average PDX Generation Time (days +/- SEM) | 87 ± 11 | 
| Tumor preparation | Tumor solid | 
| Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq | 
| Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC | 
| Passage QA performed | Routine QA every 2-3 passages | 
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) | 
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements | 
| Pubmed ID | 34413304 | 
| Markers | 452C | 
|---|---|
| AR | N | 
| PSA | N | 
| PSMA | N | 
| NE | Y | 
| ERG | N | 
                        This table displays curated CNVs
                        
            
                    
                    
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome | 
|---|---|---|---|---|---|---|---|
| 452C | PTEN | -0.975886 | 1.01686 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 | 
| 452C | SUFU | -0.975886 | 1.01686 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 | 
| 452C | MDM2 | 4.34787 | 40.7258 | gain-high | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 | 
| 452C | CHD7 | 0.67073 | 3.18376 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 | 
| 452C | MYC | 0.556691 | 2.94178 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 | 
Clinical Information
| Sample Number | 452C | 
|---|---|
| Sample Site | Prostate | 
| Sample source | Transurethral resection of the prostate | 
| Pathology Tumor Diagnosis | None | 
| Gleason Score | None | 
| Primary Gleason Score | None | 
| Secondary Gleason Score | None | 
| Tertiary Gleason Score | None | 
| ISUP Grade Group | |
| Tumor Grade | |
| D'Amico Risk Classification | |
| Tumor Volume (in cc) | 0.0 | 
| Treatment Prior to Specimen Collection | PRRT LuTate and Y-Tate, Octreotide | 
Patient Information
| Patient Number | 426/452 | 
|---|---|
| Sex | Male | 
| Diagnosis | Prostate Cancer | 
| PSA at diagnosis (ng/mL) | NA | 
| Consent to share data | |
| Patient Tumor Collection (Current Model) | |
|---|---|
| Tumour sample ID | 452C | 
| Patient Age (binned in 5 year age groups) | 25-29 | 
                        This table displays curated sequence variants
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
                    The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
| PDX ID | Gene Symbol | Depth | ALT_FREQ | Consequence | Exon | GnomAD_AF | CADD_PHRED | Clinvar_clnsig | Platform | Experiments Name | Reference | Library Type | Instrument Type | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 452C | NCOR1 | 351 | 0.65 | missense_variant | '25/46 | 0.0006336 | 22.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | BRCA1 | 631 | 0.59 | missense_variant | '10/24 | 0.0002605 | 17.67 | Benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | BRCA1 | 528 | 0.59 | missense_variant | '10/24 | 0.0002845 | 0.005 | Benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | BRCA1 | 459 | 0.58 | missense_variant | '7/24 | 0.000264 | 24.7 | Benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | FOXA1 | 438 | 0.54 | missense_variant | '2/2 | 4.07E-06 | 25.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | DICER1 | 513 | 0.52 | missense_variant | '25/29 | . | 27.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | LATS2 | 334 | 0.5 | missense_variant | '8/8 | 4.12E-06 | 25.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | FOXA2 | 438 | 0.47 | stop_gained | '2/2 | . | 48 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
| 452C | FOXA2 | 438 | 0.47 | stop_gained | '2/2 | . | 48 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 | 
                No information in Gene expression 
            
            
            
            
        
                No information in Drug dosing Table
            
            
            A
        web-based Atlas of Patient-Derived Xenografts
        of cancer patients:A resource of MURAL PDX data
 A
        web-based Atlas of Patient-Derived Xenografts
        of cancer patients:A resource of MURAL PDX data
      